Inovio Pharmaceuticals (NASDAQ:INO) Announces Earnings Results, Misses Expectations By $0.29 EPS

Inovio Pharmaceuticals (NASDAQ:INO) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.29), FiscalAI reports. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $2.27 million.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio received FDA accelerated approval for VOCERYQ, its first commercial product and the first FDA-approved plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). In the FDA’s analysis of 26 patients with at least three prior-year surgeries, 27% required no surgery in the 12 months after treatment; the company also cited durable responses and a generally favorable tolerability profile.
• Inovio is preparing a U.S. launch, with product availability expected about 60 days after approval and full field deployment targeted for Q1 2027. Management estimates at least 25,000 adult RRP patients in the U.S. and says its planned field team is designed to reach 90% of patient potential, though payer coverage and uptake estimates are based on company research.
• VOCERYQ’s accelerated approval requires a confirmatory study to verify clinical benefit, and continued approval may depend on its results. Inovio plans to submit a draft protocol by year-end and aims to agree on a final design with the FDA by mid-2027; the study is expected to include at least 50 adult and pediatric patients.
• After an equity offering that generated about $80.5 million in net proceeds, plus quarter-end cash and subsequent warrant exercises, Inovio expects to fund operations into late Q4 2027, excluding potential VOCERYQ revenue or future fundraising. The company reported Q3 operating expenses of $19.8 million, down from $21.2 million a year earlier; its $49.2 million net loss was primarily driven by a non-cash warrant fair-value adjustment.

Inovio Pharmaceuticals Stock Down 1.4%

INO stock traded down $0.02 during mid-day trading on Thursday, reaching $1.46. 1,839,239 shares of the stock traded hands, compared to its average volume of 4,858,846. Inovio Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $2.72. The business has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.27. The firm has a market capitalization of $160.31 million, a PE ratio of -2.69 and a beta of 1.71.

Top Inovio Pharmaceuticals Stories

Here are a few of the latest stories about INO:

• Neutral Sentiment: Piper Sandler maintained its Overweight rating but lowered its price target to $6 from $8. The revised target remains well above the recent share price, though the reduction may temper optimism. Piper Sandler recommendations
• Neutral Sentiment: Inovio is scheduled to participate in upcoming investor conferences, which may provide opportunities to discuss its launch plans but does not represent a new business development. Upcoming investor conferences
• Negative Sentiment: For the third quarter, Inovio reported a loss of $0.50 per share, wider than the $0.21 loss analysts expected. Revenue of $0.30 million also fell short of the $2.27 million consensus, highlighting ongoing financial pressure as the company prepares to commercialize VOCERYQ. Inovio Q3 earnings results

Wall Street Analysts Forecast Growth

INO has been the topic of a number of recent analyst reports. Piper Sandler reissued an “overweight” rating and issued a $6.00 price objective (down from $8.00) on shares of Inovio Pharmaceuticals in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $8.00 target price (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 6th. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.33.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.